Expertise in
19
conditions

Dr. Richard Roseff

Rheumatology
Healthnomic Partners/Sagebrush Health
105 Newtown Rd, 
Danbury, CT 
Expertise in
19
conditions
Healthnomic Partners/Sagebrush Health
105 Newtown Rd, 
Danbury, CT 

Overview

Richard Roseff is a Rheumatologist in Danbury, Connecticut. Dr. Roseff is highly rated in 19 conditions, according to our data. His top areas of expertise are Axial Spondyloarthritis (AxSpA), Ankylosing Spondylitis, Rheumatoid Pneumoconiosis, and Rheumatoid Lung Disease.

His clinical research consists of participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Rheumatology

Licenses

Internal Medicine in CT

Hospital Affiliations

Danbury Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Healthnomic Partners/Sagebrush Health
105 Newtown Rd, Danbury, CT 06810

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials
Similar Doctors
Expertise in
19
conditions
Dr. Robert F. Spiera
Rheumatology
Expertise in
19
conditions
Dr. Robert F. Spiera
Rheumatology

HSS - Belaire Building

525 East 71st Street, 7th Floor, 
New York, NY 
 (80.5 miles away)
212-860-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Spiera is a Rheumatologist in New York, New York. Dr. Spiera is highly rated in 19 conditions, according to our data. His top areas of expertise are Systemic Sclerosis (SSc), Vasculitis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica. Dr. Spiera is currently accepting new patients.

Expertise in
35
conditions
Dr. Alice Gottlieb
Rheumatology
Expertise in
35
conditions
Dr. Alice Gottlieb
Rheumatology

Gramercy Park Physicians LLP

10 Union Sq E, 
New York, NY 
 (83.4 miles away)
212-844-8800
Languages Spoken:
English
See accepted insurances

Alice Gottlieb is a Rheumatologist in New York, New York. Dr. Gottlieb is highly rated in 35 conditions, according to our data. Her top areas of expertise are Psoriasis, Plaque Psoriasis, Generalized Pustular Psoriasis (GPP), and Hidradenitis Suppurativa.

Expertise in
6
conditions
Dr. Monique E. Hinchcliff
Rheumatology
Expertise in
6
conditions
Dr. Monique E. Hinchcliff
Rheumatology

Yale University

6 Devine St, 
North Haven, CT 
 (16.5 miles away)
203-287-6100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Monique Hinchcliff is a Rheumatologist in North Haven, Connecticut. Dr. Hinchcliff is highly rated in 6 conditions, according to our data. Her top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Raynaud Phenomenon, Scleroma, and Tissue Biopsy.

Frequently Asked Questions about Dr. Richard Roseff

How do I make an appointment with Dr. Richard Roseff?

You can book an appointment with Dr. Richard Roseff by calling their office at 203-743-9596. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Richard Roseff a top-rated expert for Axial Spondyloarthritis (AxSpA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Richard Roseff is classified as an Distinguished expert for Axial Spondyloarthritis (AxSpA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Richard Roseff specialize in?

While Dr. Richard Roseff is a Rheumatology, they have specific expertise in Axial Spondyloarthritis (AxSpA), Ankylosing Spondylitis, and Rheumatoid Pneumoconiosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Richard Roseff accept my insurance?

Dr. Richard Roseff accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 203-743-9596 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Roseff's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile